Publicaciones Similares
Oppotunities for orphan drugs in Latin America
There are ample opportunities for the entry of orphan drugs into the region. The size of the Latin American orphan drug market was USD 14.17 billion in 2021 and it is estimated that it will increase by 7.38% by 2026. Based on the type of drug, the biological sector dominates the orphan drug market for Latin America
Brazilian Health System
Guarantees universal access to health and finances the system through taxes through the Unified Health System (SUS) and a private sector.
Biosimilars in Brazil
Brazil has designed a set of measures to increase investment in biopharmaceutical research and is promoting the production of national biological drugs.
What is the inflation reduction act?
An In-Depth Examination of the Inflation Reduction Act: Unraveling its Purpose, Goals, and Impact on the Pharmaceutical Sector. Delve into the intricacies of this legislative initiative, understanding its imperative role in mitigating inflationary pressures. Navigate through the refined landscape of the pharmaceutical market, appreciating the nuanced changes implemented to fortify economic stability and foster enduring industry prosperity.
Chilean Health System
Contribute to preserving and improving the health of the population, especially through its personal and collective care services, which seek to be a coherent response to the health and health care needs of the various population groups.
Orphan drugs in Latin America: the case of eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome
Eculizumab It has been used in the treatment of orphan diseases, such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis
